Versant Capital Management’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $307K | Buy |
17,259
+3,560
| +26% | +$63.4K | 0.05% | 312 |
|
|
2025
Q1 | $244K | Buy |
13,699
+10,358
| +310% | +$185K | 0.04% | 356 |
|
|
2024
Q4 | $99.6K | Buy |
3,341
+880
| +36% | +$26.2K | 0.02% | 316 |
|
|
2024
Q3 | $38.5K | Sell |
2,461
-556
| -18% | -$8.69K | 0.01% | 549 |
|
|
2024
Q2 | $51.7K | Buy |
3,017
+2,917
| +2,917% | +$50K | 0.01% | 366 |
|
|
2024
Q1 | $1.56K | Buy |
+100
| New | +$1.56K | ﹤0.01% | 1427 |
|
|
2023
Q4 | – | Sell |
-35
| Closed | -$565 | – | 1981 |
|
|
2023
Q3 | $565 | Buy |
35
+33
| +1,650% | +$533 | ﹤0.01% | 1668 |
|
|
2023
Q2 | $83 | Sell |
2
-4
| -67% | -$166 | ﹤0.01% | 2034 |
|
|
2023
Q1 | $361 | Hold |
6
| – | – | ﹤0.01% | 1634 |
|
|
2022
Q4 | $440 | Hold |
6
| – | – | ﹤0.01% | 1448 |
|
|
2022
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 1577 |
|
|
2022
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 1577 |
|
|
2022
Q1 | $0 | Sell |
6
-2
| -25% | – | ﹤0.01% | 1573 |
|
|
2021
Q4 | $1K | Hold |
8
| – | – | ﹤0.01% | 1315 |
|
|
2021
Q3 | $1K | Buy |
8
+2
| +33% | +$250 | ﹤0.01% | 1329 |
|
|
2021
Q2 | $1K | Hold |
6
| – | – | ﹤0.01% | 1331 |
|
|
2021
Q1 | $1K | Hold |
6
| – | – | ﹤0.01% | 1404 |
|
|
2020
Q4 | $1K | Hold |
6
| – | – | ﹤0.01% | 1238 |
|
|
2020
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 1437 |
|
|
2020
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 1478 |
|
|
2020
Q1 | $0 | Hold |
6
| – | – | ﹤0.01% | 1565 |
|
|
2019
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 1513 |
|
|
2019
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 1523 |
|
|
2019
Q2 | $0 | Buy |
+6
| New | – | ﹤0.01% | 1611 |
|